Analysts think SLDB stock price could increase by 208%
Feb 19, 2025, 12:25 PM
-11.42%
What does SLDB do
Solid Biosciences, headquartered in Charlestown, Massachusetts, develops gene therapies for Duchenne muscular dystrophy and other cardiac diseases, employing 88 staff since its IPO on January 26, 2018. Their pipeline includes multiple gene therapy candidates and novel platform technologies.
12 analysts think SLDB stock price will increase by 207.92%. The current median analyst target is $16.32 compared to a current stock price of $5.30. The lowest analysts target is $12.12 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
